Longpre Lara 4
4 · Mirum Pharmaceuticals, Inc. · Filed Mar 18, 2024
Insider Transaction Report
Form 4
Longpre Lara
Chief Development Officer
Transactions
- Purchase
Common Stock
2019-09-10$10.64/sh+965$10,268→ 105,372 total - Sale
Common Stock
2023-01-09$20.62/sh−1,003$20,684→ 104,369 total
Footnotes (2)
- [F1]The weighted average purchase price for the transaction reported was $10.64, and the range of prices were between $10.20 and $10.8799. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
- [F2]Shares sold to cover tax witholding obligations associated with the vesting of restricted stock units.